Table 4.

Frequency of CTSL, 53BP1, and VDR expression within BRCA1- and BRCA2-related tumors

Proteins	Mutation type	n (%)	Fisher exact test p-value (vs. sporadics)	Fisher exact test p-value (BRCA1 vs. BRCA2)
Nuclear CTSL >0	BRCA1 mutation (−4)	12 (85.7)	0.0001	0.10
	BRCA2 mutation (−1)	7 (53.8)	0.13
53BP1 <150	BRCA1 mutation (−1)	2 (11.8)	0.0019	0.0001
	BRCA2 mutation (−1)	11 (84.6)	0.0210
Nuclear VDR <120	BRCA1 mutation (−1)	3 (16.7)	0.0027	0.0051
	BRCA2 mutation (−1)	8 (72.7)	0.35

Values denote the absolute (n) and the relative (%) frequencies of BRCA1- or BRCA2-related tumors with Hscore values above (nuclear CTSL) or below (nuclear 53BP1 and VDR) the median Hscore values for each protein in sporadic breast tumors. Bolded p-values highlight the statistically significant difference measured by Fisher exact test comparing a molecular subtype with either the overall population of sporadic breast cancer or between tumors with BRCA1 versus BRCA2 germline mutations.